RLMD

Conviction 32HealthcareScan · Thu, Sep 24, 2026

Relmada Therapeutics, Inc. (RLMD) closed at $3.81 (+0.66%) on Sep 24, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 32, RS Rating 96, -51.6% from its 52-week high, -12.9% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.

RLMD$3.81+0.66%

ResistanceSupportVol 14Insider buy

Vol MA14 1.52M

Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24

RELMADA THERAPEUTICS, INC.PHARMACEUTICAL PREPARATIONSwww.relmada.com ↗

Price3.81

Change+0.66%

Gap-1.85%

Rel volume2.20×

Avg volume1.32M

Avg $ vol5.58M

SMA 204.27

SMA 504.70

SMA 2005.47

Price vs 50-19.11%

Price vs 200-30.50%

MA stackbearish

50/200 cross—

Supertrenddown · 4.50

RSI (14)32

MACD hist-0.02

MACD crossbear · 1d

Stoch %K / %D11 / 16

ADX (14)32

+DI / −DI14 / 33

RSI divergenceBullish

MACD divergence—

ATR %6.44%

ADR %5.06%

52w high7.86

52w low1.65

From 52w high-51.59%

Above 52w low+130.61%

New 52w highNo

SqueezeOff

Bollinger width20.01%

%B-0.04

Donchian pos11.05%

Donchian high4.65

Donchian low3.70

AVWAP (52w high)5.79

vs AVWAP high-34.32%

AVWAP (52w low)5.45

vs AVWAP low-30.22%

OBV trendDown

Chaikin MF (20)-0.12

Today vs 20d2.20×

Avg vol (14d)1.52M

Avg vol (20d)1.32M

Avg $ vol (20d)5.58M

Market cap405.88M

RS Rating96 / 99

RS 3m (vs SPY)-45.50%

RS 6m (vs SPY)-59.69%

RS line new highNo

Trend template3/8

Technical rank9.8

1 week-9.40%

1 month-17.10%

3 months-41.01%

6 months-42.87%

1 year+127.84%

YTD-12.93%

P/E-7.07

P/B1.97

P/S—

P/FCF-8.86

EPS-1.45

Div yield—

ROE-27.78%

ROA-26.20%

Debt/Eq—

Current29.52

EV/EBITDA—

Gross margin21.31%

Net margin—

Rev growth-35.41%

EPS growth28.25%

Price target12.00

Target upside215.37%

Analyst ratingBuy

Institutional105.58%

Ent. value394.54M

Revenue682

Net income-12.91M

Gross profit-3

Free cash flow-45.79M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out104.89M

Employees17

ListedMon, Mar 3, 2014

Free float91.98M

Float %87.7%

Short interest13.6M

Days to cover17.7d

Short volume53.8%

Squeeze score79 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.11 vs −$0.21

Last surprise+47.6% beat

Setup gradeD

Conviction32 / 100

Pattern quality—

Tech rank9.8 / 100

Group rank59 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance5.28

Support4.03

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in RLMD

All disclosures →

No recent disclosed trades by Congress in RLMD. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in RLMD · open-market 4 buys

Insider	Side	Shares	Value	Traded	Filed
TRAVERSA SERGIO Chief Executive Officer · Common Stock · 2026-09-10	Buy	100K	$410K	2026-09-10	2026-09-11
Shenouda Maged Chief Financial Officer · Common Stock · 2026-09-10	Buy	79.8K	$339K	2026-09-10	2026-09-11
TRAVERSA SERGIO Chief Executive Officer · Common Stock · 2026-09-09	Buy	100K	$418K	2026-09-09	2026-09-11
Shenouda Maged Chief Financial Officer · Common Stock · 2026-09-09	Buy	120.2K	$505K	2026-09-09	2026-09-11

SEC filings

EDGAR filings in RLMD · 8 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.